Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)

Masahito Kotaka; Yoji Saito; Takeshi Kato; Hironaga Satake; Akitaka Makiyama; Yasushi Tsuji; Katsunori Shinozaki; Toshiyoshi Fujiwara; Tsunekazu Mizushima; Yasushi Harihara; Naoki Nagata; Naoto Kurihara; Masahiko Ando; Genichi Kusakawa; Takumi Sakai; Yugo Uchida; Mikihiro Takamoto; Saki Kimoto; Ichinosuke Hyodo

doi:10.1007/s00280-020-04185-y

Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)

Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Yasushi Tsuji, Katsunori Shinozaki, Toshiyoshi Fujiwara, Tsunekazu Mizushima, Yasushi Harihara, Naoki Nagata, Naoto Kurihara, Masahiko Ando, Genichi Kusakawa, Takumi Sakai, Yugo Uchida, Mikihiro Takamoto, Saki Kimoto, Ichinosuke Hyodo

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below:Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The leastsquares mean FACT/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day ART [vs. placebo: 7.3 (95% CI 1.9 to 12.8, p = 0.009)], and 32.3 with 3-day ART [vs. placebo: 3.4 (95% CI −2.1 to 9.0, p = 0.222)].

Original language	English
Pages (from-to)	585-586
Number of pages	2
Journal	Cancer Chemotherapy and Pharmacology
Volume	87
Issue number	4
DOIs	https://doi.org/10.1007/s00280-020-04185-y
Publication status	Published - Apr 2021

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-020-04185-y

Fingerprint

Dive into the research topics of 'Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)'. Together they form a unique fingerprint.

Cite this

Kotaka, M., Saito, Y., Kato, T., Satake, H., Makiyama, A., Tsuji, Y., Shinozaki, K., Fujiwara, T., Mizushima, T., Harihara, Y., Nagata, N., Kurihara, N., Ando, M., Kusakawa, G., Sakai, T., Uchida, Y., Takamoto, M., Kimoto, S., & Hyodo, I. (2021). Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8). Cancer Chemotherapy and Pharmacology, 87(4), 585-586. https://doi.org/10.1007/s00280-020-04185-y

Correction to : A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8). / Kotaka, Masahito; Saito, Yoji; Kato, Takeshi et al.

In: Cancer Chemotherapy and Pharmacology, Vol. 87, No. 4, 04.2021, p. 585-586.

Research output: Contribution to journal › Comment/debate › peer-review

Kotaka, M, Saito, Y, Kato, T, Satake, H, Makiyama, A, Tsuji, Y, Shinozaki, K, Fujiwara, T, Mizushima, T, Harihara, Y, Nagata, N, Kurihara, N, Ando, M, Kusakawa, G, Sakai, T, Uchida, Y, Takamoto, M, Kimoto, S & Hyodo, I 2021, 'Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)', Cancer Chemotherapy and Pharmacology, vol. 87, no. 4, pp. 585-586. https://doi.org/10.1007/s00280-020-04185-y

Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y et al. Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8). Cancer Chemotherapy and Pharmacology. 2021 Apr;87(4):585-586. doi: 10.1007/s00280-020-04185-y

Kotaka, Masahito ; Saito, Yoji ; Kato, Takeshi et al. / Correction to : A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8). In: Cancer Chemotherapy and Pharmacology. 2021 ; Vol. 87, No. 4. pp. 585-586.

@article{bd2615e030924b859896fd61078e973b,

title = "Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)",

abstract = "In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below:Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The leastsquares mean FACT/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day ART [vs. placebo: 7.3 (95% CI 1.9 to 12.8, p = 0.009)], and 32.3 with 3-day ART [vs. placebo: 3.4 (95% CI −2.1 to 9.0, p = 0.222)].",

author = "Masahito Kotaka and Yoji Saito and Takeshi Kato and Hironaga Satake and Akitaka Makiyama and Yasushi Tsuji and Katsunori Shinozaki and Toshiyoshi Fujiwara and Tsunekazu Mizushima and Yasushi Harihara and Naoki Nagata and Naoto Kurihara and Masahiko Ando and Genichi Kusakawa and Takumi Sakai and Yugo Uchida and Mikihiro Takamoto and Saki Kimoto and Ichinosuke Hyodo",

note = "Publisher Copyright: {\textcopyright} 2020, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2021",

month = apr,

doi = "10.1007/s00280-020-04185-y",

language = "English",

volume = "87",

pages = "585--586",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Correction to

T2 - A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)

AU - Kotaka, Masahito

AU - Saito, Yoji

AU - Kato, Takeshi

AU - Satake, Hironaga

AU - Makiyama, Akitaka

AU - Tsuji, Yasushi

AU - Shinozaki, Katsunori

AU - Fujiwara, Toshiyoshi

AU - Mizushima, Tsunekazu

AU - Harihara, Yasushi

AU - Nagata, Naoki

AU - Kurihara, Naoto

AU - Ando, Masahiko

AU - Kusakawa, Genichi

AU - Sakai, Takumi

AU - Uchida, Yugo

AU - Takamoto, Mikihiro

AU - Kimoto, Saki

AU - Hyodo, Ichinosuke

PY - 2021/4

Y1 - 2021/4

N2 - In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below:Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The leastsquares mean FACT/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day ART [vs. placebo: 7.3 (95% CI 1.9 to 12.8, p = 0.009)], and 32.3 with 3-day ART [vs. placebo: 3.4 (95% CI −2.1 to 9.0, p = 0.222)].

AB - In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below:Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The leastsquares mean FACT/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day ART [vs. placebo: 7.3 (95% CI 1.9 to 12.8, p = 0.009)], and 32.3 with 3-day ART [vs. placebo: 3.4 (95% CI −2.1 to 9.0, p = 0.222)].

UR - http://www.scopus.com/inward/record.url?scp=85094964611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094964611&partnerID=8YFLogxK

U2 - 10.1007/s00280-020-04185-y

DO - 10.1007/s00280-020-04185-y

M3 - Comment/debate

C2 - 33136172

AN - SCOPUS:85094964611

VL - 87

SP - 585

EP - 586

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -

Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this